Lurasidone-d8

Lurasidone-d8 is intended for use as an internal standard for the quantification of lurasidone (Cay-9000570) by GC- or LC-MS. Lurasidone is an atypical antipsychotic that binds to dopamine D2, serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT1A, and 5-HT7, and alpha2C-adrenergic receptors (Kis = 1.68, 2.03, 6.75, 0.495, and 10.8 nM, respectively). In vivo, pre-training administration of lurasidone (1 and 3 mg/kg) reverses impairment in step-through latency and passive avoidance in a foot shock test induced by MK-801 (Cay-10009019) in rats. It reverses MK-801-induced learning impairment in the Morris water maze as well as reference and working memory impairment in the radial arm maze in rats. Lurasidone also decreases immobility in the tail suspension and forced swim tests, indicating antidepressant-like activity in mice. Formulations containing lurasidone have been used in the treatment of schizophrenia and mood disorders.Formal Name: (3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl-2,2,3,3,5,5,6,6-d8]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione. CAS Number: 1132654-54-6. Molecular Formula: C28H28D8N4O2S. Formula Weight: 500.7. Purity: >99% deuterated forms (d1-d8). Formulation: (Request formulation change), A solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml. SMILES: [H][C@@]1(C2=O)[C@]([C@H]3CC[C@@H]1C3)([H])C(N2C[C@@H]4CCCC[C@H]4CN5C([2H])([2H])C([2H])([2H])N(C6=NSC7=C6C=CC=C7)C([2H])([2H])C5([2H])[2H])=O. InChi Code: InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1/i11D2,12D2,13D2,14D2. InChi Key: PQXKDMSYBGKCJA-KBFPQGGWSA-N.